NRX Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by NRX Pharmaceuticals, Inc. (NRXP) on November 20, 2025. The report discloses a change in the company's independent registered public accounting firm. The company is incorporated in Delaware and its securities trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the administrative change of the external auditor.
Material Changes
- Engagement of New Auditor: The Audit Committee approved the engagement of Weinberg & Company P.A. ("Weinberg") as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Dismissal of Prior Auditor: Salberg & Company P.A. ("Salberg") was dismissed as the independent registered public accounting firm on or around November 24, 2025.
- Reason for Change: Weinberg had previously audited Dura Medical LLC, a subsidiary acquired by Hope Therapeutics, Inc., which is a subsidiary of NRX Pharmaceuticals.
Outlook, Risks, and Contingencies
Audit Opinions: Salberg's audit reports for the fiscal years ended December 31, 2024, and December 31, 2023, did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles. However, the audit opinion included an explanatory paragraph regarding the Company's ability to continue as a going concern.
Disagreements: The company reported no "disagreements" or "reportable events" with Salberg during the two most recent fiscal years and the interim period through September 30, 2025. Salberg confirmed its agreement with these statements in a letter filed as Exhibit 16.1.
Investor Verification Checklist
- Verify the "going concern" explanatory paragraph noted in the prior audit reports to understand the specific liquidity or operational risks cited.
- Review the transition timeline between Salberg and Weinberg to ensure no gaps in audit coverage for the 2025 fiscal year.
- Confirm the status of the Hope Therapeutics, Inc. subsidiary and the integration of Dura Medical LLC's financials under the new auditor.
- Monitor upcoming filings (10-K or 10-Q) for the first financial statements audited by Weinberg & Company P.A.